<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19872" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Congenital Toxoplasmosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kota</surname>
            <given-names>Archana S.</given-names>
          </name>
          <aff>Nassau University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shabbir</surname>
            <given-names>Nadeem</given-names>
          </name>
          <aff>Nassau University Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Archana Kota declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nadeem Shabbir declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19872.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Toxoplasmosis is a parasitic infection in humans and animals. Infection in healthy immunocompetent adults is asymptomatic in about 50% of the cases. However, it can also cause a self-limited mild, nonspecific illness presenting with signs and symptoms such as fever, malaise, maculopapular rash, headache, fatigue, and tender lymphadenopathy. In immunocompromised individuals and neonates, it causes a severe infection with devastating sequelae. This activity reviews the identification, evaluation, and management of congenital toxoplasmosis and explains the role of the interprofessional team in managing and improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the risk factors for acquiring congenital toxoplasmosis and understand its pathophysiology.</p></list-item><list-item><p>Evaluate&#x000a0;the common physical exam findings associated with congenital toxoplasmosis.</p></list-item><list-item><p>Determine&#x000a0;the risks and benefits associated with the antiparasitic regimen and summarize key patient counseling points.</p></list-item><list-item><p>Communicate&#x000a0;the importance of improving care coordination amongst interprofessional team members to improve outcomes for patients affected by congenital toxoplasmosis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19872&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19872">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19872.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Toxoplasmosis is a parasitic infection in humans and animals. Infection in healthy immunocompetent adults is asymptomatic in about 50% of the cases. However, it can also cause a self-limited mild, nonspecific illness presenting with signs and symptoms such as fever, malaise, maculopapular rash, headache, fatigue, and tender lymphadenopathy.&#x000a0; In immunocompromised individuals and neonates, it causes a severe infection with devastating sequelae. Congenital toxoplasmosis, as a result of vertical transmission from infected mothers, is a significant cause of morbidity and mortality in fetuses, neonates, and children as they progress into adulthood. Since asymptomatic infection is more common, a high index of suspicion is necessary, and diagnosis can be made readily by serologic testing.</p>
      </sec>
      <sec id="article-19872.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Congenital toxoplasmosis results from a protozoan, an obligate ubiquitous intracellular parasite, <italic toggle="yes">Toxoplasma gondii (T. gondii)</italic>.</p>
        <p>
<bold>Life cycle</bold>
</p>
        <p>The definitive hosts of <italic toggle="yes">T. gondii</italic> are cats with a wide range of intermediate hosts. In cats, it can have 2 cycles, intestinal and extraintestinal, whereas, in other hosts, it has only an extraintestinal phase.&#x000a0;The&#x000a0;life cycle of&#x000a0;<italic toggle="yes">T. gondii&#x000a0;</italic>has 3 infectious stages: tachyzoite, bradyzoite, and oocysts or sporozoites. Bradyzoites and tachyzoites are slow and fast multiplying phases in the host's tissues, mainly the brain and muscle. Oocysts form from the sexual cycle of the organism in the cat&#x02019;s intestine. Cats typically get infected by consuming infected animals containing bradyzoites or contaminated soil or water containing oocysts. The parasite replicates in the gut of the cat to produce oocysts.</p>
        <p>In this acute phase of intestinal infection, the cat sheds millions of oocysts in their feces for about 1 to 2 weeks. These oocysts sporulate under ideal humid environmental conditions and contaminate the soil, grass, and garden vegetables. It usually takes 2 to 3 days in temperate climates and longer in colder climates. Thus, if the cat litter gets disposed of within 1 to 2 days, the risk of infection is decreased. Intermediate hosts such as humans, sheep, cattle, pigs, birds, and mice acquire the infection in this phase. These oocysts differentiate into tachyzoites, which are characteristic of acute infection. The transformation into oocysts (sexual cycle) occurs only in cats. Over time, they get deposited in the tissues as cysts (bradyzoites) in the intermediate hosts. Bradyzoites are responsible for latent infection and persist in the brain, myocardium, skeletal muscle, and other organs for life.</p>
        <p>
<bold>Transmission</bold>
</p>
        <p>Pregnant women develop toxoplasmosis via 2 routes:</p>
        <list list-type="order">
          <list-item>
            <p>Primary maternal infection due to the ingestion of undercooked meat or oocyst-contaminated food or water</p>
          </list-item>
          <list-item>
            <p>Reactivation of latent infection in severely immunocompromised states such as co-infection with human immunodeficiency virus</p>
          </list-item>
        </list>
        <p>The organisms are transmitted transplacentally to the growing fetus. The incubation period is 4 to 21 days in acquired infections. The exact timing of when the transmission occurs is not well documented. The severity of the clinical manifestations in the fetus and the newborn depends on the gestational age at which the infection occurs, parasitic load, the virulence of the infective strain, and the maternal immune status.<xref ref-type="bibr" rid="article-19872.r1">[1]</xref></p>
      </sec>
      <sec id="article-19872.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The number of men, women, and children in the&#x000a0;United States carrying the toxoplasma parasite exceeds 40 million, but most are asymptomatic. Worldwide, more than 60% of some populations are infected with toxoplasma. Seroprevalence is variable between different regions, being more prevalent in tropical areas. Toxoplasmosis is considered to be the most common parasitic infection in humans. Seropositivity increases with age in all geographical areas. The infection rates are often higher in regions with hot, humid climates and lower altitudes because oocysts grow faster and survive better in such an environment. The incidence of congenital toxoplasmosis depends upon the acquisition time of toxoplasma infection in pregnant women and their prior infection state at the time of exposure. Congenital cytomegalovirus (CMV) is the only transplacentally acquired infection more common than congenital toxoplasmosis. In the United States, congenital toxoplasma infection rates among live-born newborns are from 1 in 3000 to 1 in 10,000.<xref ref-type="bibr" rid="article-19872.r2">[2]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-19872.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Congenital toxoplasmosis has wide-ranging clinical manifestations from being completely asymptomatic at birth to severe neurological and ocular disease. The majority of the infants (about 75%) with congenital toxoplasmosis have no apparent clinical manifestations at birth. Identification usually takes place during routine newborn and maternal screening done in certain countries. They demonstrate neurological (cerebral calcifications) or ophthalmologic (retinal scars) abnormalities. In a limited percentage of patients, it can lead to spontaneous abortion, premature or stillbirth.</p>
        <p>Term newborns usually present with a milder form of the disease with symptoms such as hepatosplenomegaly and lymphadenopathy. In comparison, preterm newborns exhibit severe symptoms. The classic triad of chorioretinitis, hydrocephalus, and cerebral calcifications presents in a limited number of infected newborns. The symptoms are generally severe and clinically apparent when the mother acquires the infection in the first trimester and receives no treatment. Some severely affected may die in utero or a few days after birth. The signs and symptoms of severe disease include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Neurological manifestations (eg,&#x000a0;micro- or macrocephaly, seizures, nystagmus, hydrocephalus, cerebral calcifications, meningoencephalitis)&#x000a0;<xref ref-type="bibr" rid="article-19872.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Ophthalmologic manifestations (eg, chorioretinitis, microphthalmia, retinochoroiditis, strabismus)</p>
          </list-item>
          <list-item>
            <p>Small for gestational age</p>
          </list-item>
          <list-item>
            <p>Hepatosplenomegaly</p>
          </list-item>
          <list-item>
            <p>Generalized lymphadenopathy</p>
          </list-item>
          <list-item>
            <p>Jaundice</p>
          </list-item>
          <list-item>
            <p>Thrombocytopenia, anemia, petechiae</p>
          </list-item>
          <list-item>
            <p>Maculopapular rash</p>
          </list-item>
        </list>
        <p>Infants with mild or subclinical infection are at risk for late sequelae such as:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Recurring chorioretinitis resulting in vision loss</p>
          </list-item>
          <list-item>
            <p>Motor delays</p>
          </list-item>
          <list-item>
            <p>Learning disorders</p>
          </list-item>
          <list-item>
            <p>Intellectual disability</p>
          </list-item>
          <list-item>
            <p>Hearing loss</p>
          </list-item>
          <list-item>
            <p>Endocrine abnormalities due to disruption of the hypothalamus and pituitary gland &#x000a0;</p>
          </list-item>
        </list>
        <p>At present, newborn screening for congenital toxoplasmosis is performed only in Massachusetts and New Hampshire.<xref ref-type="bibr" rid="article-19872.r4">[4]</xref></p>
      </sec>
      <sec id="article-19872.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Testing for congenital toxoplasmosis in the fetus should take place when the mother has confirmed infection or there are suggestive sonographic findings such as intracranial calcifications or cerebral ventricular dilation. Positive&#x000a0;polymerase chain reaction (PCR) for <italic toggle="yes">T. gondii</italic> DNA in the amniotic fluid confirms the diagnosis in the fetus. &#x000a0;</p>
        <p>Congenital toxoplasmosis should be suspected in the newborns in the following situations:</p>
        <list list-type="bullet">
          <list-item>
            <p>Primary maternal infection with <italic toggle="yes">T. gondii</italic> during pregnancy</p>
          </list-item>
          <list-item>
            <p>Immunocompromised mothers with prior <italic toggle="yes">T. gondii</italic> infection</p>
          </list-item>
          <list-item>
            <p>Newborns with clinical features indicative of congenital toxoplasmosis</p>
          </list-item>
          <list-item>
            <p>Newborns with positive newborn screening for toxoplasma</p>
          </list-item>
        </list>
        <p>The diagnosis results from a combination of clinical and laboratory findings. &#x000a0;</p>
        <p>
<bold>Serological tests</bold>
</p>
        <p>toxoplasma<italic toggle="yes">-</italic>specific antibodies (immunoglobulin [Ig]G, IgM, and IgA) require testing in all cases of suspected infection. The half-life of toxoplasma IgM and IgA antibodies is 5 and 10 days. When there is a concern for false positives due to maternal contamination of fetal blood during labor, repeat serological testing should be done 10 days after birth. <italic toggle="yes">T. gondii</italic> DNA by PCR is also possible in cerebral spinal fluid (CSF), urine, or peripheral blood.<xref ref-type="bibr" rid="article-19872.r5">[5]</xref></p>
        <p>The diagnostic criteria for confirmed infection are one of the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Presence of toxoplasma-specific&#x000a0;IgM or IgA antibodies 10 days after birth</p>
          </list-item>
          <list-item>
            <p>Persistent or increasing IgG titer without treatment in infants at or beyond 1 year of age</p>
          </list-item>
          <list-item>
            <p>Positive PCR for <italic toggle="yes">T. gondii</italic> DNA or positive toxoplasma IgM or Ig A antibodies in the CSF</p>
          </list-item>
        </list>
        <p>Positive IgG is indicative of prior or current maternal infection. In the presence of other suggestive features but negative IgM and IgA antibodies, toxoplasma IgG testing requires repetition every 4 to 6 weeks until complete disappearance. Negative IgM and IgA antibodies do not exclude the infection. If the mother is affected later in her pregnancy, there is a delay in the production of antibodies in the newborn. When an infection is suspected, the antibodies should be repeated every 2 to 4 weeks until at least 3 months of age.</p>
        <p>Because the interpretation of these serologic tests is complex, they should be sent to the National Reference Laboratory for Toxoplasmosis (Palo Alto, CA) or the Toxoplasmosis Center (Chicago, IL) for confirmation.</p>
        <p>
<bold>Imaging</bold>
</p>
        <p>The main findings on cranial sonography or computed tomography of the head include diffuse intracranial periventricular calcifications, brain atrophy, or hydrocephalus.&#x000a0;</p>
        <p>
<bold>Other tests</bold>
</p>
        <p>CSF will be abnormal, with high protein levels (&#x0003e;1 gm/dl) and mild elevation of white blood cells with monocyte predominance. A complete blood count may demonstrate anemia or thrombocytopenia. Hepatic and renal function tests can be done as a baseline to look for other signs of systemic involvement.</p>
      </sec>
      <sec id="article-19872.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Despite being over a hundred years since the discovery of <italic toggle="yes">T. gondii</italic>, researchers have not been able to establish a standardized regimen for the treatment of congenital toxoplasmosis. There are numerous opinions regarding the drug regimens and the duration of the treatment.<xref ref-type="bibr" rid="article-19872.r6">[6]</xref></p>
        <p>Most medications work against the actively dividing tachyzoites and do not work against encysted bradyzoites. The most commonly used treatment regimen in confirmed and probable cases of congenital toxoplasmosis is a combination of pyrimethamine, a sulphonamide (sulphadiazine or sulphadoxine), and folinic acid for 1 year.<xref ref-type="bibr" rid="article-19872.r7">[7]</xref> Higher doses and longer duration (2 years) are recommended when the presentation is severe, with over three intracerebral calcifications and/or more than one ocular sign or severe abnormalities at birth. Newer drugs known to have activity against <italic toggle="yes">T. gondii</italic> are azithromycin and atovaquone. However, more research is needed to determine its efficacy. If diagnosed prenatally, the mother should be treated immediately before the delivery. Spiramycin is recommended for mothers with acute toxoplasma infection to prevent transplacental transmission.<xref ref-type="bibr" rid="article-19872.r8">[8]</xref></p>
        <p>Asymptomatic infants with positive serology or newborn screening receive treatment for 3 months. Some experts recommend adding steroids to this regimen when the CSF protein is high or severe chorioretinitis affects vision. Steroid therapy continues until the protein in the CSF disappears or the chorioretinitis resolves. The infants must be followed with frequent neurodevelopmental, ophthalmologic, and hearing assessments to evaluate the therapy response and identify any late sequelae.</p>
        <p>The long duration of treatment is associated with adverse medication effects such as severe bone marrow suppression resulting in neutropenia, worsening kidney function, and allergic reactions. These infants should have frequent blood count monitoring and periodic liver and renal function tests.<xref ref-type="bibr" rid="article-19872.r9">[9]</xref></p>
      </sec>
      <sec id="article-19872.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Congenital toxoplasmosis requires differentiation from other congenital infections caused by:</p>
        <list list-type="bullet">
          <list-item>
            <p>CMV</p>
          </list-item>
          <list-item>
            <p>Rubella</p>
          </list-item>
          <list-item>
            <p>Lymphocytic choriomeningitis virus</p>
          </list-item>
          <list-item>
            <p>Varicella</p>
          </list-item>
          <list-item>
            <p>Herpes simplex virus</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19872.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Prenatal treatment of toxoplasmosis reduces the risk of severe presentation and late neurological sequelae. The prognosis of untreated toxoplasmosis is very poor, resulting in vision deficits, neurological deficits, and severe developmental delays.<xref ref-type="bibr" rid="article-19872.r10">[10]</xref> The prognosis in treated patients remains an area of significant research. Some studies have demonstrated that early treatment substantially improves the ocular lesions. However, they need close ophthalmologic monitoring through early adulthood.<xref ref-type="bibr" rid="article-19872.r11">[11]</xref> Higher gestational age correlates with better outcomes.</p>
      </sec>
      <sec id="article-19872.s10" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of untreated congenital toxoplasmosis include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Loss of vision</p>
          </list-item>
          <list-item>
            <p>Deafness</p>
          </list-item>
          <list-item>
            <p>Intellectual disability</p>
          </list-item>
          <list-item>
            <p>Severe developmental delays</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19872.s11" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>
<bold>Prevention&#x000a0;</bold>
</p>
        <p>Pregnant women should be educated to prevent toxoplasmosis; counseling points include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Wear gloves or wash hands when handling litter boxes, and to not adopt or pet stray cats</p>
          </list-item>
          <list-item>
            <p>Avoid eating undercooked meat during pregnancy</p>
          </list-item>
          <list-item>
            <p>Peel and wash fruits and vegetables before consumption</p>
          </list-item>
          <list-item>
            <p>Avoid contact with soil or wear gloves when gardening</p>
          </list-item>
          <list-item>
            <p>Avoid drinking unfiltered water</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19872.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The identification and management of congenital toxoplasmosis continue to be challenging. Early treatment is the cornerstone of improved morbidity. This condition is best managed by an interprofessional group of medical professionals that includes a neonatologist, neurologist, Infectious disease specialist, ophthalmologist, developmental pediatrician, primary care pediatrician, and care coordinator.</p>
        <p>The key is prevention, and this requires an interprofessional approach. The pregnant female requires education on washing hands after touching meat products and not consuming undercooked or raw meat. Also, all fruits and vegetables require thorough washing. The female should avoid contact with cat litter and fecal material. Educational reinforcement should come from the nurses, pharmacists, obstetricians, and primary caregivers at every clinic visit. Only through such an approach can the morbidity of congenital toxoplasmosis be reduced.</p>
        <p>Given the lack of a solid pharmaceutical approach to treatment, the pharmacist should monitor the regimen closely, checking dosing and agent selection, performing medication reconciliation, and informing the team should they encounter any issues. Nurses will be best positioned to monitor for adverse events or evaluate the effectiveness of treatment. Only through an interprofessional team approach, including physicians, specialists, specialty-trained nurses, and pharmacists, all collaborating across disciplines, can patients achieve optimal patient results.&#x000a0;</p>
      </sec>
      <sec id="article-19872.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19872&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19872">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/congenital-toxoplasmosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=19872">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19872/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19872">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-19872.s14">
        <fig id="article-19872.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Congenital toxoplasmosis Image courtesy O. Chaigasame</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="congenital__toxo" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-19872.s15">
        <title>References</title>
        <ref id="article-19872.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kieffer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wallon</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Congenital toxoplasmosis.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2013</year>
            <volume>112</volume>
            <fpage>1099</fpage>
            <page-range>1099-101</page-range>
            <pub-id pub-id-type="pmid">23622316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19872.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robert-Gangneux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dard&#x000e9;</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of and diagnostic strategies for toxoplasmosis.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>264</fpage>
            <page-range>264-96</page-range>
            <pub-id pub-id-type="pmid">22491772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19872.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Congenital toxoplasmosis: An overview of the neurological and ocular manifestations.</article-title>
            <source>Parasitol Int</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>67</volume>
            <issue>6</issue>
            <fpage>715</fpage>
            <page-range>715-721</page-range>
            <pub-id pub-id-type="pmid">30041005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19872.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guerina</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Meissner</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Maguire</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lynfield</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stechenberg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Abroms</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pasternack</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Hoff</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eaton</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group.</article-title>
            <source>N Engl J Med</source>
            <year>1994</year>
            <month>Jun</month>
            <day>30</day>
            <volume>330</volume>
            <issue>26</issue>
            <fpage>1858</fpage>
            <page-range>1858-63</page-range>
            <pub-id pub-id-type="pmid">7818637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19872.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pomares</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Montoya</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Laboratory Diagnosis of Congenital Toxoplasmosis.</article-title>
            <source>J Clin Microbiol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>54</volume>
            <issue>10</issue>
            <fpage>2448</fpage>
            <page-range>2448-54</page-range>
            <pub-id pub-id-type="pmid">27147724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19872.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilbert</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Treatment for congenital toxoplasmosis: finding out what works.</article-title>
            <source>Mem Inst Oswaldo Cruz</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>104</volume>
            <issue>2</issue>
            <fpage>305</fpage>
            <page-range>305-11</page-range>
            <pub-id pub-id-type="pmid">19430658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19872.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maldonado</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Read</surname>
                <given-names>JS</given-names>
              </name>
              <collab>COMMITTEE ON INFECTIOUS DISEASES</collab>
            </person-group>
            <article-title>Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States.</article-title>
            <source>Pediatrics</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>139</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">28138010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19872.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montoya</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Liesenfeld</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Toxoplasmosis.</article-title>
            <source>Lancet</source>
            <year>2004</year>
            <month>Jun</month>
            <day>12</day>
            <volume>363</volume>
            <issue>9425</issue>
            <fpage>1965</fpage>
            <page-range>1965-76</page-range>
            <pub-id pub-id-type="pmid">15194258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19872.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carellos</surname>
                <given-names>EVM</given-names>
              </name>
              <name>
                <surname>de Andrade</surname>
                <given-names>JQ</given-names>
              </name>
              <name>
                <surname>Romanelli</surname>
                <given-names>RMC</given-names>
              </name>
              <name>
                <surname>Tib&#x000fa;rcio</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Janu&#x000e1;rio</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Vasconcelos-Santos</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Figueiredo</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>de Andrade</surname>
                <given-names>GMQ</given-names>
              </name>
              <collab>UFMG Congenital Toxoplasmosis Brazilian Group (UFMG-CTBG)</collab>
            </person-group>
            <article-title>High Frequency of Bone Marrow Depression During Congenital Toxoplasmosis Therapy in a Cohort of Children Identified by Neonatal Screening in Minas Gerais, Brazil.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>36</volume>
            <issue>12</issue>
            <fpage>1169</fpage>
            <page-range>1169-1176</page-range>
            <pub-id pub-id-type="pmid">28151845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19872.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olariu</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Remington</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Montoya</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Severe congenital toxoplasmosis in the United States: clinical and serologic findings in untreated infants.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>30</volume>
            <issue>12</issue>
            <fpage>1056</fpage>
            <page-range>1056-61</page-range>
            <pub-id pub-id-type="pmid">21956696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19872.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garweg</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Abrahamowicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cornu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vinault</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Quantin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bonithon-Kopp</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Picot</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peyron</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Binquet</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Ophthalmic outcomes of congenital toxoplasmosis followed until adolescence.</article-title>
            <source>Pediatrics</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>133</volume>
            <issue>3</issue>
            <fpage>e601</fpage>
            <page-range>e601-8</page-range>
            <pub-id pub-id-type="pmid">24534412</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
